arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Atea Pharmaceuticals, Inc.

AVIR
$5.16 ▼ -0.12 (-2.37%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
32 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Atea Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $413.1M
Dividend Yield —
Revenue Growth —
Op. Margin None
ROIC -17.2% ↗
FCF / Share $-0.46 ↗
Trailing P/E —
Price / Book 2.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 24, 2026.

32-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$192.18M
↑ +485.7% —
Net Income Profit after all expenses
$-45.44M
↓ -32.6% —
Operating Margin Operating profit as % of sales
63.1%
↑ +193.4% —
FCF / Share Free cash flow per share
$-0.46
↑ +20.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 9 years · 32 quarters